Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PHIBRO ANIMAL HEALTH CORPPAHC · Entity 4671 | Director · Executive Chairman · 10% owner | August 06, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PHIBRO ANIMAL HEALTH CORP
Report date August 06, 2026 · Filed August 10, 2026
Jointly reported with BFI Co., LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 26,640 |
Reported balance
After 2026-08-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-06 · Grant · Acquired 12,103 · Balance 26,640 F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. F3: The reported securities are directly held by Jack Bendheim. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee | 56,152 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 56,152 F4: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.
F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date.
F3: The reported securities are directly held by Jack Bendheim.
F4: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2017 Filed Jun 16, 2017 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 16,000 | $34.65 | $554,400.00 |
DisclosureSEC source: 0001144204-17-032805 · v469063_form4.xml · nonDerivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 48,000 F3 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2016. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.35 to $35.00, inclusive. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 707 | $35.41 | $25,034.87 |
DisclosureSEC source: 0001144204-17-032805 · v469063_form4.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 64,000 F3 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2016. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.40 to $35.45, inclusive. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 15,293 | $34.96 | $534,643.28 |
DisclosureSEC source: 0001144204-17-032805 · v469063_form4.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 64,707 F3 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2016. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.40 to $35.35, inclusive. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 13, 2017 Filed Jun 16, 2017 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 48,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-032805 · v469063_form4.xml · derivative · entry 6 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 20,718,836 Underlying: Class A Common Stock · 48,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time after issuance on a one-for-one basis, and has no expiration date. F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time after issuance on a one-for-one basis, and has no expiration date. F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time after issuance on a one-for-one basis, and has no expiration date. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 13, 2017 Filed Jun 16, 2017 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 16,000 | $34.84 | $557,440.00 |
DisclosureSEC source: 0001144204-17-032805 · v469063_form4.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 80,000 F3 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.55 to $35.15, inclusive. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 13, 2017 Filed Jun 16, 2017 01:19 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-032805 · v469063_form4.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 96,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time after issuance on a one-for-one basis, and has no expiration date. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 09, 2017 Filed Jun 10, 2017 00:03 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 16,000 | $35.71 | $571,360.00 |
DisclosureSEC source: 0001571049-17-005850 · t1704044_x1-bendheim.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 48,000 F3 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2016. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.25 to $36.00, inclusive. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 08, 2017 Filed Jun 10, 2017 00:03 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 16,000 | $35.56 | $568,960.00 |
DisclosureSEC source: 0001571049-17-005850 · t1704044_x1-bendheim.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 64,000 F3 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2016. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.25 to $35.85, inclusive. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 07, 2017 Filed Jun 10, 2017 00:03 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 48,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001571049-17-005850 · t1704044_x1-bendheim.xml · derivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 20,766,836 Underlying: Class A Common Stock · 48,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time after issuance on a one-for-one basis, and has no expiration date. F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time after issuance on a one-for-one basis, and has no expiration date. F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time after issuance on a one-for-one basis, and has no expiration date. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 07, 2017 Filed Jun 10, 2017 00:03 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 16,000 | $35.60 | $569,600.00 |
DisclosureSEC source: 0001571049-17-005850 · t1704044_x1-bendheim.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 80,000 F3 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.10 to $35.95, inclusive. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 07, 2017 Filed Jun 10, 2017 00:03 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001571049-17-005850 · t1704044_x1-bendheim.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 96,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Class B Common Stock is convertible into Class A Common Stock at any time after issuance on a one-for-one basis, and has no expiration date. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 25, 2017 Filed May 26, 2017 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 16,000 | $34.80 | $556,800.00 |
DisclosureSEC source: 0001571049-17-005398 · t1701708_x1.xml · nonDerivative · entry 4 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 48,000 F3 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on March 14, 2016. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.50 to $35.15, inclusive F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 24, 2017 Filed May 26, 2017 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 16,000 | $34.75 | $556,000.00 |
DisclosureSEC source: 0001571049-17-005398 · t1701708_x1.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 64,000 F3 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on March 14, 2016. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.35 to $35.03, inclusive. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 23, 2017 Filed May 26, 2017 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass B Common Stock · Derivative | 72,975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001571049-17-005398 · t1701708_x1.xml · derivative · entry 5 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 20,814,836 Underlying: Class A Common Stock · 72,975 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_price: The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis, and had no expiration date. F1 · price: The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 23, 2017 Filed May 26, 2017 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 16,000 | $34.46 | $551,360.00 |
DisclosureSEC source: 0001571049-17-005398 · t1701708_x1.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 80,000 F3 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on March 14, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $34.65, inclusive. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 23, 2017 Filed May 26, 2017 01:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | ConversionClass A Common Stock | 72,975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001571049-17-005398 · t1701708_x1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 96,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis, and had no expiration date. F1 · price: The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 19, 2017 Filed May 20, 2017 01:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 16,000 | $34.16 | $546,560.00 |
DisclosureSEC source: 0001571049-17-005185 · t1701639_x1-bendheim.xml · nonDerivative · entry 3 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 23,025 F2 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on March 14, 2016. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.50, inclusive F1 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 18, 2017 Filed May 20, 2017 01:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 16,000 | $34.09 | $545,440.00 |
DisclosureSEC source: 0001571049-17-005185 · t1701639_x1-bendheim.xml · nonDerivative · entry 2 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 39,025 F2 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on March 14, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.35, inclusive. F1 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 17, 2017 Filed May 20, 2017 01:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 16,000 | $34.20 | $547,200.00 |
DisclosureSEC source: 0001571049-17-005185 · t1701639_x1-bendheim.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 55,025 F2 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on March 14, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.50, inclusive. F1 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 10, 2017 Filed May 13, 2017 00:00 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 1,400 | $34.04 | $47,656.00 |
DisclosureSEC source: 0001571049-17-004977 · t1701563-x1.xml · nonDerivative · entry 1 BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 71,025 F2 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on March 14, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.05, inclusive. F1 · ownership.nature: The securities are held by BFI Co., LLC. Mr. Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI Co., LLC and may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.